Drug Approval | February 22, 2022
The facility will manufacture its Herceptin biosimilar, Tuznue
The transaction as well as the open offer is expected to be completed by June this year.
The sale is expected to close in the first quarter of 2022
Essential products manufactured by Sartorius, using Sü dpack polymer films made from Dow resins, support safe and effective vaccine production for global vaccine supply
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
The brand has added a range of exciting new products especially formulated for oily skin.
The agreement also had a permanent safeguard mechanism which can be resorted to in a situation of sudden surge in imports.
Subscribe To Our Newsletter & Stay Updated
